Performing laparoscopic sleeve gastrectomy in an obese patient with systemic lupus erythematosus undergoing long-term steroid therapy: a case report

Atsushi Gakuhara1*, Yasuhiro Miyazaki1, Yukinori Kurokawa1, Tsuyoshi Takahashi1, Makoto Yamasaki1, Tomoki Makino1, Koji Tanaka1, Kiyokazu Nakajima1, Masaki Mori2 and Yuichiro Doki1

Abstract

Background: Systemic lupus erythematosus (SLE), an autoimmune disease characterized by systemic inflammatory lesions, is often associated with obesity. Obesity aggravates symptoms of SLE; however, these symptoms can be improved by weight loss through diet therapy and bariatric surgery. However, there are only a few reports regarding the effectiveness of bariatric surgery in obese patients with SLE. Herein, we discuss the laparoscopic sleeve gastrectomy (LSG) performed in an obese patient with SLE while undergoing long-term steroid therapy.

Case presentation: A 36-year-old female, suffering from SLE for 10 years with effects on the central nervous system, developed diabetes mellitus (DM) triggered by the steroid therapy for SLE. The patient was undergoing steroid therapy (6 mg/day) for SLE since a long time. For DM management, her HbA1c level was maintained at 7.4%. She was 158 cm tall and 91.6 kg in weight. Her body mass index was 36.7. She could not work and depended on welfare services. To improve her obesity and DM, physicians suggested that she should undergo bariatric surgery in our hospital. Eventually, she underwent LSG, which lasted for 185 min, with minimal blood loss and without complications. Her blood glucose level stabilized immediately after the surgery; hence, her antidiabetic medication was discontinued. She was discharged 8 days after surgery, and her weight decreased steadily. In the first year after surgery, her weight was 54.4 kg, and she had lost approximately 37 kg from her initial weight. Her steroid requirement had also reduced to 4 mg/day. Through weight loss, she could begin to work and became a part of society again.

Conclusion: LSG was safely performed in an obese patient with SLE undergoing long-term steroid therapy. We noted substantial weight loss, improved DM condition, and reduced requirement of SLE therapy after surgery. Hence, surgical risks must be carefully examined before patients undergo bariatric surgery.

Keywords: Systemic lupus erythematosus, Bariatric surgery, Laparoscopic sleeve gastrectomy
Background
Systemic lupus erythematosus (SLE), an autoimmune disease characterized by systemic inflammatory lesions caused by tissue deposition of immune complexes such as DNA-anti-DNA antibodies, is often associated with obesity [1, 2]. Symptoms of SLE are worsened by obesity but can improve by weight loss through diet therapy [3]. Bariatric surgery is another effective way to reduce weight. However, only a few reports concerning the effectiveness of bariatric surgery on obese patients with SLE [4, 5]. Patients with SLE often undergo long-term steroid therapy, which poses a high surgical risk [6–8]. Herein, we report the case of an obese patient with SLE undergoing long-term steroid therapy in whom laparoscopic sleeve gastrectomy (LSG) was successfully performed.

Case presentation
A 36-year-old female, suffering from SLE since 10 years with effects on her central nervous system, developed diabetes mellitus (DM) 9 years ago, triggered by her long-term steroid therapy for SLE. She was undergoing steroid treatment (6 mg/day) for SLE at a different hospital. She was 158 cm tall and weighed 91.6 kg. Her body mass index was 36.7, indicating 3° higher obesity. To manage DM, she was treated with metformin, and her HbA1c was controlled at 7.4%. Serum immuno-reactive insulin (IRI) and C-peptide immunoreactivity (CPR) levels were 13.8 μU/ml and 2.5 ng/ml, respectively. Both the markers were in normal range. Total cholesterol (T-chol), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) levels were 191 mg/dL, 86 mg/dL, 41 mg/dL, and 126 mg/dL, respectively. Her dyslipidemia was well controlled by administering atorvastatin. She had no hypertension as a complication of obesity. She was also treated with paroxetine hydrochloride hydrate, mianserin hydrochloride, and sodium valproate for steroid-induced depression. She could not work and depended on welfare services. To improve her obesity and DM, physicians suggested that she should undergo bariatric surgery in our hospital. She understood bariatric surgery well, and the symptoms of SLE were well controlled and stable, and she had no symptoms of central nervous system lupus. Anti-DNA and anti-Sm antibody levels were > 2.0 IU/ml and 2.5 U/ml, respectively. Both the SLE markers were in normal range. CH50, C3, and C4 levels were 53.8 U/ml, 144 mg/dL, and 26 mg/. All the SLE markers were in normal range, and SLE activity was well controlled as per laboratory data. She was given a diet instruction by her previous doctor but was unable to lose weight. Her obesity was considered to include an element of secondary obesity due to steroids. However, there were several studies reporting that patients with SLE who were obese were able to reduce their steroid dose along with reduction in their weight after bariatric surgery. Therefore, this case was judged to be an indication for bariatric surgery. Preoperative weight loss techniques were demonstrated at our outpatient clinic. She was treated with Mazindol and given diet instruction by a dietitian. She was able to lose 7 kg while continuing nutritional guidance for approximately 5 months. She was admitted in our hospital a week before the surgery, and her blood glucose was controlled. Thereafter, she underwent LSG, which lasted for 185 min, with a minimal blood loss and without complications. For the perioperative steroid cover, 200 mg of hydrocortisone sodium succinate was administered immediately before the surgery, and the maintenance dose (6 mg/day) was resumed on the first postoperative day. She was discharged on the eighth postoperative day without complications. Her blood glucose level stabilized immediately after the surgery; hence, her antidiabetic medication was stopped. After being discharged, she experienced gradual weight loss. After a year, she weighed 54.4 kg, losing approximately 37 kg, compared with her weight during the initial examination; additionally, rebound effects were not manifested (Fig. 1a). Body fat mass was also markedly reduced 1 year after the surgery compared with her preoperative status; meanwhile, her skeletal muscle mass was maintained (Fig. 2). Furthermore, SLE condition was stable, and her steroid requirement was reduced to 4 mg/day (Fig. 1c). After surgery, her blood glucose level had settled down; thus, her DM drug therapy was halted. Her DM improved up to 5.7% of HbA1c 1 year after the surgery (Fig. 1b). Her dyslipidemia was well controlled by atorvastatin. T-chol, TG, HDL-C, and LDL-C levels were 165 mg/dL, 43 mg/dL, 48 mg/dL, and 104 mg/dL, respectively. For her steroid-induced depression, paroxetine hydrochloride hydrate and mianserin hydrochloride were reduced by half, and sodium valproate medication was terminated 9 months after surgery. Through weight loss, she could begin to work and be part of the society again.

Discussion
We were able to perform LSG safely for the obese patient with SLE undergoing long-term steroid therapy. Postoperatively, she had successfully lost weight, her DM improved, and her steroid dose was reduced. Ultimately, she became part of the society again.

The prevalence of SLE is higher in women than in men; of note, female population is six times larger than male population [9]. Regarding race, Asian and African populations are larger than Caucasian population [10]. SLE can be improved by administering NSAIDs, steroids, or immunosuppressive drugs; however, this condition is a refractory disease that subsides and relapses repeatedly. Long-term steroid use can lead to various unfavorable
effects, such as cardiovascular lesions, DM, obesity, and infectious diseases, which lower the patient’s quality of life and prognosis [11, 12].

Regarding the relationship between SLE and obesity, two thirds of patients with SLE were overweight or obese [2]. In obese patients with SLE, functional ability and health-related quality of life are lower than that in normal weighing patients with SLE [13, 14]. In addition, the inflammatory marker is high [13]. Diet therapy had reportedly improved the SLE symptoms of a patient; hence, weight loss may be effective in ameliorating such symptoms in obese patients [3].

Bariatric surgery does not only promote weight reduction on severe obesity but also improve DM and metabolic
syndromes [15]. Weight loss after bariatric surgery results in anti-inflammatory effects; in fact, bariatric surgery was performed for inflammatory bowel disease, and anti-inflammatory effects were manifested [16]. However, the effect of bariatric surgery on patients with SLE in Western Europe has been rarely reported [4, 5]. Corcelles et al. reported 1 gastric banding, 23 Roux-en-Y gastric bypass, 3 revisional surgery, and 3 LSG cases, with postoperative weight loss and possibility of therapeutic agent reduction. Bariatric surgery may be a possible treatment for SLE with obesity. The occurrence of anti-inflammatory effects due to weight loss may indicate the effectiveness of bariatric surgery for patients with SLE. However, the type of bariatric surgery that can yield optimal results is still unknown. Previous reports stated that silicon exposure causes a newly identified syndrome called autoimmune/inflammatory syndrome, which is induced by adjuvants and may subsequently develop into various systemic autoimmune diseases, such as SLE and rheumatoid arthritis; thus, this technique should be avoided [17, 18]. To our knowledge, our report is the first in Asia, and it shows that bariatric surgery for obese patients with SLE may be effective as well in Asians. Moreover, complications increase with respect to surgical risks for patients with autoimmune diseases, especially those who are using immunosuppressive drugs for a long time [6–8]. A steroid cover is also required in perioperative management; thus, we need to be cautious during perioperative management. In this case, by replacing corticosteroids on the day of surgery and restarting steroid therapy immediately after surgery, she showed a good postoperative course and no complications. Surgery indication should be decided after careful examination of a surgical risk.

**Conclusion**

LSG was safely performed in such obese patient with SLE undergoing long-term steroid therapy. Postoperative weight loss was achieved, her DM improved, and her SLE therapy drugs were reduced. Thus, a careful examination on the surgical risks of patients is necessary before surgery and before selecting the appropriate procedure.

**Abbreviations**

DM: Diabetes mellitus; LSG: Laparoscopic sleeve gastrectomy; SLE: Systemic lupus erythematosus

**Acknowledgements**

Not applicable.

**Authors’ contributions**

YM performed the surgery, AG drafted the manuscript, YM revised it critically, and YK, TT, KT, TM, MY, KN, MA, and YD conceived of the study and participated in its design and coordination and helped to draft the manuscript. All authors approved the final manuscript.

**Funding**

None.

**Availability of data and materials**

Not applicable.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Written informed consent was obtained from the patient for publication of this case report and accompanying images.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, 2-2, E-2, Yamadaoka, Suita City, Osaka 565-0871, Japan.

2 Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-ku, Fukuoka City 812-8582, Japan.

**Received:** 15 August 2019 **Accepted:** 16 October 2019

**Published online:** 29 October 2019

**References**

1. Chung CP, Avalos I, Oeser A, et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann Rheum Dis. 2007;66(2):208–14.

2. dos Santos FM, Borge’s MC, Corella MI, et al. Assessment of nutritional status and physical activity in systemic lupus erythematosus patients. Rev Bras Reumatol. 2010;50(6):631–8.

3. Davies RJ, Lomer MC, Yeo SI, et al. Weight loss and improvements in fatigue in systemic lupus erythematosus: a controlled trial of a low glycaemic index diet versus a calorie restricted diet in patients treated with corticosteroids. Lupus. 2012;21(6):649–55.

4. Gagné DJ, Papasavas PK, Dowec EA, et al. Effect of immunosuppression on surgery indications. Surgery indication should be decided after careful examination of a surgical risk.

5. Corcelles R, Daigle CR, Talamas HR, et al. Bariatric surgery outcomes in patients with systemic lupus erythematosus. Surg Obes Relat Dis. 2015;11(3):684–8.

6. Busti AJ, Hooper JS, Amaya CL, et al. Effects of perioperative antiflammatory and immunomodulating therapy on surgical wound healing. Pharmacotherapy. 2005;25(11):1566–91.

7. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008;20(2):131–7.

8. Lin JA, Liao CC, Lee YJ, et al. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study. Ann Rheum Dis. 2014;73(9):1646–51.

9. Rees F, Doherty M, Grainge M, et al. The incidence and prevalence of systemic lupus erythematosus in the UK, 1999–2012. Ann Rheum Dis. 2016;75(1):136–41.

10. Rees F, Doherty M, Grainge MJ, et al. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017;56(1):1945–61.

11. Urowitz MB, Klareskog L, Gladman DD. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol. 2007;34(1):70–5.

12. Davidson JE, Fu Q, Rao S, et al. Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort. Lupus Sci Med. 2018;5(1):e000237.

13. Oeser A, Chung CP, Asanuma Y, et al. Obesity is an independent contributor to functional capacity and inflammation in systemic lupus erythematosus. Arthritis Rheum. 2005;52(1):351–9.

14. Rizk A, Gheta TA, Nasief S, et al. The impact of obesity in systemic lupus erythematosus on disease parameters, quality of life, functional capacity and the risk of atherosclerosis. Int J Rheum Dis. 2012;15(3):261–7.

15. Pöystönen CD, Liinari L, Wedel H, et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res. 1999;7(5):477–84.

16. Aminian A, Andalib A, Ver MR, et al. Outcomes of bariatric surgery in patients with inflammatory bowel disease. Obes Surg. 2016;26(8):1186–90.
17. Cohen Tervaert JW, Kappel RM. Silicone implant incompatibility syndrome (SIIS): a frequent cause of ASIA (Shoenfeld’s syndrome). Immunol Res. 2013;56(2–3):293–8.

18. Jara LJ, Medina G, Gómez-Bañuelos E, et al. Still’s disease, lupus-like syndrome, and silicone breast implants. A case of ‘ASIA’ (Shoenfeld’s syndrome). Lupus. 2012;21(2):140–5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.